Veuillez utiliser cette adresse pour citer ce document :
https://di.univ-blida.dz/jspui/handle/123456789/31563
Titre: | Transition towards Non-Invasive Treatment for Cutaneous Carcinomas |
Autre(s) titre(s): | Evaluation of 3D Dosimetry by Monte Carlo |
Auteur(s): | Mosuoe, Bokang Molefi Laoues, M. (Promoteur) |
Mots-clés: | Skin cancer treatment Superficial brachytherapy (SBT) Rhenium-188 (188Re) GATE Dosimetry |
Date de publication: | 2024 |
Editeur: | Université Blida 1 |
Résumé: | Non-melanoma skin cancer (NMSC), comprising primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is one of the most prevalent cancers globally, with its incidence rising annually. Traditional treatments, including surgical excision, cryosurgery, photodynamic therapy, and radiotherapy, have limitations such as potential for incomplete excision and cosmetic concerns. Superficial brachytherapy (SBT) with beta emissions from rhenium-188 (188Re) has emerged as a promising alternative. This study focuses on the dosimetric analysis of 188Re-based SBT using three-dimensional Monte Carlo GATE simulations to model the radiation dose distribution within treated tissues accurately. The primary objectives are to assess the safety, effectiveness, and potential clinical benefits of 188Re SBT in treating BCC and SCC. The research demonstrates that 188Re SBT achieves high treatment efficacy while minimizing impact on surrounding healthy tissues, thereby supporting its adoption as a standard therapy for NMSC and potentially improving patient outcomes and quality of life. Keywords: Skin cancer treatment, Superficial brachytherapy (SBT), Rhenium-188 (188Re), GATE, Dosimetry. |
Description: | ill., Bibliogr. Cote:ma-530-361 |
URI/URL: | https://di.univ-blida.dz/jspui/handle/123456789/31563 |
Collection(s) : | Mémoires de Master |
Fichier(s) constituant ce document :
Fichier | Description | Taille | Format | |
---|---|---|---|---|
Mosuoe Bokang Molefi.pdf | 5,83 MB | Adobe PDF | Voir/Ouvrir |
Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.